Franklin Biotechnology Discovery Fund A(acc)USD
Equity fund
1 year
USA
Largest region
High
Risk
Annual costs
Morningstar
Partial
Sustainability
Development
Last 5 years
( ann.)
Description
- Fondet investerer hovedsakelig i aksjeverdipapirer utstedt av bioteknologiselskaper av enhver størrelse , og som befinner seg i USA og i andre land Fondet kan investere i mindre omfang i gjeldsobligasjoner av høyere kvalitet utstedt av selskaper Et bioteknologiselskap er et selskap som har minst 50 % av sitt overskudd fra eller er involvert i virksomheter som forskning, utvikling, produksjon og distribusjon av ulike bioteknologiske eller biomedisinske produkter, tjenester og prosesser. Fondet vil normalt investere mer i USA enn i noe annet land.
Investment horizon
- Franklin Biotechnology Discovery Fund A(acc)USD is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.
Characteristics
- Minimum amount
- Sharpe 3 years
- Price/NAV
22 Jul 2025
- Start date02 Apr 2000
- ISINLU0109394709
Risk
- High (5 of 7)
Morningstar rating
- The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.
Sustainability
- SustainabilityPartial
Costs
- Ongoing costs
Includes management fees of 1,50 %
- Platform fee
- Kickback fee
- Annual running costs
- Performance-based fee
Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.
Allocation
- Stocks 96%Interest 4%
Portfolio
Shows the fund's largest investments.
- Gilead Sciences Inc7.8%
- Vertex Pharmaceuticals Inc6.8%
- Amgen Inc6.0%
- Ascendis Pharma AS ADR5.1%
- Regeneron Pharmaceuticals Inc4.5%
- Insmed Inc4.1%
- argenx SE ADR3.9%
- Jazz Pharmaceuticals PLC3.5%
- Alnylam Pharmaceuticals Inc3.3%
- Merus NV3.2%